Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.» Read More
Some readers will accuse me of finding any old excuse to write about Dendreon, which as I've blogged before always results in a spike in page views. But on a day when nearly all of biopharma is under pressure again due to market forces, it's truly worth calling attention...
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.
This morning the world's biggest biotech company released the highly-anticipated detailed test results on its crucial, late-stage experimental osteoporosis drug known as D-mab. And they look good.
Yesterday afternoon I became a statistic. I am now among the reportedly growing number of people getting injured while texting and--not driving--but walking.
I finished my last ImClone Systems vs. Bristol-Myers Squibb entry asking what Bristol had to say about IMCL's claim of a mystery outbidder. Well, yesterday we found out in a press release from BMY.
Of all the places to put money to work in Europe, the pharmaceutical sector is the most promising, a technical analyst told CNBC Thursday.
At the Thomson Reuters/BioCentury investment conference some hedge fund guy, who I'd never met before and who will remain unidentified, whispered in my ear that there's gonna be a bidding war for ImClone Systems.
When the majors need to cut costs, they turn to Covance.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.
Earlier this week I blogged about Eli Lilly's "Coming Soon" banner ad I spotted in the online edition of "The New England Journal of Medicine." It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month.
Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.
One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.
Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.
After Medivation, I moved onto the Orexigen presentation. It's a company I profiled at when it had data on one of its fat-fighting drugs at last year's diabetes conference, so I wanted to check up on its progress.
A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.
Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.
In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).
While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."
Two reports and an editorial in "The New England Journal of Medicine" are raising questions again about the potentially higher risk of death from cancer associated with a popular cholesterol-fighting drug.